方盛制药：子公司瑞卢戈利片临床试验获批

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug aimed at treating advanced prostate cancer, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Fangsheng Pharmaceutical announced on October 15 that its wholly-owned subsidiary, Fangsheng Jianmeng, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the drug RuLuGoli Tablets [1] - RuLuGoli Tablets are classified as gonadotropin-releasing hormone (GnRH) receptor antagonists, specifically designed for the treatment of adult advanced prostate cancer [1]